Barcelona, Spain: Patients with a type of breast cancer called HER2-positive are less likely to survive if their initial treatment fails to eradicate the tumour completely and they have high levels of immune cells called tumour infiltrating lymphocytes in the residual disease.
Dr Federica Miglietta told the 13th European Breast Cancer Conference that normally tumour infiltrating lymphocytes (TILs) help the body’s immune system to fight cancer cells. However, for this particular breast cancer, which is driven by human epidermal growth factor 2 (HER2) receptors on the surface of the cancer cells, post-treatment TILs seemed to be counter-productive if any disease remained after patients had received chemotherapy and anti-HER2 therapy before surgery (known as ‘neoadjuvant treatment’).
“In patients with HER2-positive breast cancer undergoing neoadjuvant treatment, higher levels of tumour infiltrating lymphocytes when patients are first diagnosed are known to be associated with a greater likelihood of the cancer disappearing from the breast and the axillary lymph nodes and with improved survival,” said Dr Miglietta, who is a research fellow at the University of Padua and a medical oncologist at the Istituto Oncologico Veneto, Italy. “However, there have been conflicting data on the role of TILs in patients who still have residual disease after neoadjuvant treatment.”
Cancer researchers have become increasingly interested in the role of the immune system in cancer and ways to harness it to fight the disease. Therefore, Dr Miglietta and her colleagues looked at data from 295 HER2-positive breast cancer patients who had been treated at three Italian centres between 2001 and 2021: Istituto Oncologico Veneto, Azienda Unità Sanitaria Locale di Reggio Emilia and IRCCS Humanitas Research Hospital – Humanitas Cancer Center. Sixty-six per cent of patients (195) had residual disease after neoadjuvant treatment. Information on the amount of residual disease (‘residual cancer burden’) and TILs in the residual tumours was available for 180 and 159 patients, respectively.
“We evaluated the levels of TILs in surgical samples of residual disease after neoadjuvant treatment and also assessed their prognostic role,” said Dr Miglietta. “We found that overall survival for patients with HER2-positive breast cancer, who had TILs on more than 15% of the surface area of their tumour, was significantly shorter than patients with lower levels of TILs.”
Sixty-eight per cent of patients with high levels of TILs in their residual disease were alive after five years compared to 84% of patients with low levels of TILs.
“We know that the tumour is surrounded by the so-called tumour microenvironment, like a complex ecosystem where tumour cells and the patient’s normal cells, including immune cells, affect and shape one another. Our results suggest that the immune microenvironment of residual disease, after exposure to chemotherapy and anti-HER2-targeted therapy, promotes the growth of cancer cells rather than fighting against them, and this phenomenon seems to profoundly affect the natural history of the disease,” said Dr Miglietta.
She said these findings applied only to HER2-positive breast cancer and not to other types of breast cancer.
“The fact that higher levels of TILs in residual disease is associated with worse outcomes seems to be a distinct feature of HER2-positive cancer. Indeed, the opposite has been consistently reported for triple negative breast cancer. This suggests that the behaviour of the residual disease immune microenvironment is highly dynamic and is strictly related to breast cancer type and exposure to treatment.”
The researchers used the information on TILs, residual disease burden (‘residual cancer burden’) and patient outcomes to develop a prognostic model for reliably predicting the probability of overall survival.
“This provides a more accurate tool to stratify patients properly from a prognostic point of view so that we can know how the disease is likely to evolve and this information can be potentially used, if validated, to plan treatments accordingly following neoadjuvant therapy and surgery. Our new prognostic model is associated with overall survival, which represents one of the most reliable and clinically relevant pieces of information for cancer patients and their doctors,” she said.
If the prognostic model is validated by further studies, it could not only improve predictions of outcomes for patients with HER2-positive breast cancer where neoadjuvant treatment has failed to completely eradicate cancer cells, but it could also be used to re-define objectives for new clinical trials of neoadjuvant therapies and to identify patients suitable for other treatments when the neoadjuvant treatments are ineffective.
Strengths of the study include the fact that it is multi-centre, that the patients had the same type of breast cancer and neoadjuvant treatment, and that the presence of TILs was evaluated in a standardised way. Limitations include that it is a retrospective study and not all patients received the current standard adjuvant treatments.
The researchers are planning a more comprehensive evaluation of the composition of TILs, an analysis of gene expression to identify genomic differences that are associated with the levels of TILs and their composition after neoadjuvant treatment, and a validation of their results in larger, prospective studies.
President of the European Breast Cancer Council, Professor David Cameron, from the University of Edinburgh Cancer Research Centre, UK, represents the Council at EBCC13 and was not involved with the research. He commented: “The role of the immune system in cancer has been interesting us for some time. We have seen that some cancers respond well to drugs, such as checkpoint inhibitors, that help the immune system to recognise and kill cancer cells. In HER2-positive breast cancer, it appeared that higher levels of tumour infiltrating lymphocytes predicted better responses and outcomes in patients. But, until now, people had not really looked at cancer that has not been cleared by treatment. This study suggests that TILs in the residual disease are not good news.
“We don’t know if this result will be seen in other studies but, if it is, it suggests that there is something dysfunctional about the immune system in these cases because having more lymphocytes does not seem to help. This shows that the story of the immune system and breast cancer may be more complex than we suspected.”
Abstract no: 4, “A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study”, Friday, closing plenary session, 15.30-16.30 hrs CET, Rooms 113-116.
The research was funded by the University of Padova, Italy.
EBCC is the largest breast cancer conference outside the USA. It aims to provide a unique multidisciplinary setting for all professionals with a common interest in breast cancer to discuss, debate, inform and educate themselves about this evolving disease. Approximately 1,500 breast cancer stakeholders from about 80 countries will come together to share the most recent scientific knowledge.